myeloma

(redirected from myeloma protein)
Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to myeloma protein: plasma cell myeloma, monoclonal protein

my·e·lo·ma

 (mī′ə-lō′mə)
n. pl. my·e·lo·mas or my·e·lo·ma·ta (-mə-tə)
A malignant tumor formed by the cells of the bone marrow.

my′e·lo′ma·toid′ (-toid′) adj.

myeloma

(ˌmaɪɪˈləʊmə)
n, pl -mas or -mata (-mətə)
(Pathology) a usually malignant tumour of the bone marrow or composed of cells normally found in bone marrow
ˌmyeˈlomaˌtoid adj

my•e•lo•ma

(ˌmaɪ əˈloʊ mə)

n., pl. -mas, -ma•ta (-mə tə)
a tumor of plasma cells, arising in bone marrow and often occurring at multiple sites.
[1855–60]
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.myeloma - a tumor of the bone marrow (usually malignant) composed of cells normally found in bone marrow
malignant neoplasm, malignant tumor, metastatic tumor - a tumor that is malignant and tends to spread to other parts of the body
multiple myeloma - myeloma that develops in several places at the same time
Translations

my·e·lo·ma

n. mieloma.
1. cualquier tumor de la médula espinal u ósea;
2. tumor formado por el tipo de células que se encuentran en la médula ósea;
multiple ______ múltiple.

myeloma

n mieloma m; multiple — mieloma múltiple
References in periodicals archive ?
IgD myeloma protein with "unreactive" light chain determinants.
Multiple Myeloma is a neoplastic disease of the plasma cells characterized by clonal proliferation of terminally differentiated B lymphoid cells, which accumulate in bone marrow and produce a monoclonal protein (Immunoglobulin), usually IgG or IgA, often referred to as M or myeloma protein. Multiple Myeloma comprises 10% of all haematological malignancies and 1% of all neoplastic disorders with usual age of presentation in 6th and 7th decade of life.
In particular, physicians should measure myeloma protein, as multiple studies have demonstrated a relationship between the presence of myeloma proteins after radiation and progression of solitary plasmacytoma to multiple myeloma.
According to the National Cancer Institute (NCI), MM is staged by estimating the myeloma tumor cell mass on the basis of the amount of monoclonal myeloma protein (M protein) in the serum and/or urine, along with various clinical parameters, such as hemoglobin and serum calcium concentrations, the number of lytic bone lesions, and the presence or absence of renal failure.
A Monoclonal gammopathy of undetermined significance (MGUS) is the term used to denote the presence of a monoclonal protein (M-protein, myeloma protein, or paraprotein) in persons without evidence of plasma-cell myeloma, Waldenstrom macroglobulinemia, primary amyloidosis, or related disorders.
Multiple myeloma is characterized by a proliferation of plasma cells that produce M proteins and an overproduction of myeloma protein and immunoglobulin.
Of the 180 patients treated with thalidomide, 30% achieved at least a 50% reduction in levels of paraproteins (serum myeloma protein or urine Bence Jones protein).